Union Budget 2024: Mixed reactions from healthcare and medical industry experts
Reactions range from praise for cancer drug cost cuts to demands for stronger R&D incentives, reflecting varied views on health policy.
Read More
Budget provides customs duty exemptions for three cancer treatment drugs
FM proposes customs duty changes on X-ray components, ₹2,143 crore PLI for pharma, and continued focus on NCDs and health research.
Read More
Union budget 2024: Family welfare schemes get a major boost
Health budget sees modest rise, but family welfare up 35%, cancer drugs get duty relief, and MedTech input duty cuts aim to boost affordability.
Read More
Limited mention of healthcare sector in Union Budget 2024; Longstanding demands go unaddressed: Experts
Industry sought higher health spend, tax cuts, and medical tourism push, but welcomed duty exemptions on three cancer drugs and BCD relief.
Read More
Government eases rules for global sourcing of medical gear
Govt allows global tenders for 354 medical devices, citing lack of domestic options to improve access to advanced healthcare technology.
Read More
Navigating the Complexities of Medical Device Pricing: Insights from Pavan Choudary
In an interview, MTaI chief Pavan Choudary discusses key factors the NPPA should consider in shaping a fair medical device pricing framework.
Read More
Can price control create treatment Bias?
Stent price caps may have cut costs but risk unintended treatment biases, cost-shifting, and overuse, raising concerns about patient harm.
Read More
Medical device bodies welcome CDSCO order on self-reporting adverse effects
Device makers welcome CDSCO’s push for MvPI adverse-event reporting, but stress the need for systematic reviews and follow-up.
Read More
Medical device companies get a three-month extension for licences
CDSCO grants a 3-month licence extension to Class C & D medical device makers and importers who applied by Sept 30, 2023.
Read More